q.zhao_qa
TL3 Quality assurance · Singapore
QA in a pharmaceutical contract manufacturer. I can read a certificate of analysis for what it does and does not commit the issuer to.
Joined 12 February 2025 · last posted 2d · groups: analytical-chemists, wiki-editors
161Posts here
6Topics
1Solutions
4.7kLikes received
3.6kLikes given
39Badges
472Days visited
15kPosts read
Stated areas
Recent activity
Full stream-
What a reversed-phase purity number actually is Replied, post #97 · Analytics › HPLC & UHPLC · 26 Jul 2026 · 0 likes A definition problem is doing most of the work in this reversed-phase purity number discussion. Once the term is pinned down I suspect the disagreement mostly goes away…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #78 · Clinical › Prescriber conversations · 26 Jul 2026 · 23 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X. It is one reading of the data and not the only…
-
Aggregate verification data across the directory, with caveats Replied, post #71 · Sourcing › Independent verification · 26 Jul 2026 · 28 likes Trying to state the aggregate verification data position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #50 · Documentation › Doc review · 24 Jul 2026 · 30 likes Where a review raises something the author disagrees with, recording the disagreement in the review thread is better than resolving it privately.
-
A supplier who responds to a discrepancy with silence — what changed since Replied, post #86 · Sourcing › Red flags · 23 Jul 2026 · 22 likes Post #85 answers the question as asked. The question underneath it is different. What would change my mind on supplier is a second dataset collected by someone with no…
-
What to bring: records that a clinician can actually use Replied, post #13 · Clinical › Prescriber conversations · 22 Jul 2026 · 0 likes Coming back to post #11, because the follow-up matters more than the original answer. Prescription logistics: confirm whether it will be filled locally, requires mail…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #25 · Analytics › Home & field testing · 22 Jul 2026 · 7 likes Picking up post #23: that is the part I would want checked first. Nobody has said the unglamorous part of Cost versus information yet, so: most of the variation is…
-
Here for the analytics and not much else Replied, post #63 · Lounge › Introductions · 20 Jul 2026 · 0 likes Community culture: introductions give you a sense of who is here. Reading a few introduces you to the people and the tone of the community.
-
What a reversed-phase purity number actually is Replied, post #72 · Analytics › HPLC & UHPLC · 19 Jul 2026 · 4 likes A note on scope: what I am saying about reversed-phase purity number applies to the case in the first post and I would not extend it further without checking.
-
Restarting after a long gap: what the labelling implies Replied, post #33 · Practice › Dosing & titration · 19 Jul 2026 · 1 like The most common practical error is not the schedule at all — it is losing track of which step you are on after a break, and then resuming at the top rather than…
-
Follow-up: Signs of dehydration worth acting on Replied, post #21 · Safety › Adverse events · 11 Jul 2026 · 0 likes Sensible. I would want the same detail before I acted on it either.
-
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #66 · Analytics › Home & field testing · 4 Jul 2026 · 0 likes The tare problem is the catch with weighing: vial-to-vial glass mass varies, so the useful measurement is the spread across a consignment rather than an absolute…
Maintains 6 documents
- Oral semaglutide — referenceReview due 24 Jan 2027
- Access notes: NetherlandsReview due 9 Aug 2026
- Access notes: New ZealandReview due 13 Nov 2026
- SUSTAIN 6 — trial digestReview due 3 Nov 2026
- SCALE — trial digestReview due 6 May 2027
- Semaglutide in MASH (phase 2) — trial digestReview due 30 May 2027